Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients

References

1. Chryssanthou E. 1997; In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B.Acquired resistance to itraconazole. Scand J Infect Dis 29:509–512 [CrossRef]
   [Google Scholar]
2. Dannaoui E., Borel E., Persat F., Monier M. F., Piens M. A. 1999a; In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis.EBGA Network. European Research Group on Biotypes and Genotypes of Aspergillus fumigatus . J Med Microbiol 48:1087–1093 [CrossRef]
   [Google Scholar]
3. Dannaoui E., Persat F., Monier M. F., Borel E., Piens M. A., Picot S. 1999b; In-vitro susceptibility of Aspergillus spp.isolates to amphotericin B and itraconazole. J Antimicrob Chemother 44:553–555 [CrossRef]
   [Google Scholar]
4. Dannaoui E., Borel E., Monier M. F., Piens M. A., Picot S., Persat F. 2001; Acquired itraconazole resistance in Aspergillus fumigatus . J Antimicrob Chemother 47:333–340 [CrossRef]
   [Google Scholar]
5. Denning D. W. 1998; Invasive aspergillosis. Clin Infect Dis 26:781–803 [CrossRef]
   [Google Scholar]
6. Denning D. W., Venkateswarlu K., Oakley K. L., Anderson M. J., Manning N. J., Stevens D. A., Warnock D. W., Kelly S. L. 1997; Itraconazole resistance in Aspergillus fumigatus . Antimicrob Agents Chemother 41:1364–1368
   [Google Scholar]
7. Denning D. W., Marinus A., Cohen J. & 11 other authors; 1998; An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome.EORTC Invasive Fungal Infections Cooperative Group. J Infect 37:173–180 [CrossRef]
   [Google Scholar]
8. Denning D. W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., Haas A., Ruhnke M., Lode H. 2002; Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571 [CrossRef]
   [Google Scholar]
9. Deresinski S. C., Stevens D. A. 2003; Caspofungin. Clin Infect Dis 36:1445–1457 [CrossRef]
   [Google Scholar]
10. Espinel-Ingroff A., Bartlett M., Bowden R. & 16 other authors; 1997; Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol 35:139–143
    [Google Scholar]
11. Georgopapadakou N. H., Walsh T. J. 1994; Human mycoses: drugs and targets for emerging pathogens. Science 264:371–373 [CrossRef]
    [Google Scholar]
12. Hachem R. Y., Raad I. I., Afif C. M., Negroni R., Graybill J., Hadley S., Kantarjian H., Adams S., Mukwaya G. 2000; An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections (IFI)refractory (R) to or intolerant (I) to standard therapy (ST). In Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada; 2000 Abstract 1109 pp 372 Washington, DC: American Society for Microbiology;
    [Google Scholar]
13. Johnson E. M., Oakley K. L., Radford S. A., Moore C. B., Warn P., Warnock D. W., Denning D. W. 2000; Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother 45:85–93 [CrossRef]
    [Google Scholar]
14. Lass-Florl C., Kofler G., Kropshofer G., Hermans J., Kreczy A., Dierich M. P., Niederwieser D. 1998; In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 42:497–502 [CrossRef]
    [Google Scholar]
15. Mehrad B., Paciocco G., Martinez F. J., Ojo T. C., Iannettoni M. D., Lynch J. P. III 2001; Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest 119:169–175 [CrossRef]
    [Google Scholar]
16. Moore C. B., Sayers N., Mosquera J., Slaven J., Denning D. W. 2000; Antifungal drug resistance in Aspergillus . J Infect 41:203–220 [CrossRef]
    [Google Scholar]
17. Moosa M. Y., Alangaden G. J., Manavathu E., Chandrasekar P. H. 2002; Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis. J Antimicrob Chemother 49:209–213 [CrossRef]
    [Google Scholar]
18. Mosquera J., Warn P. A., Morrissey J., Moore C. B., Gil-Lamaignere C., Denning D. W. 2001; Susceptibility testing of Aspergillus flavus : inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob Agents Chemother 45:1456–1462 [CrossRef]
    [Google Scholar]
19. NCCLS (National Committee for Clinical Laboratory Standards) 1998; Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-forming Filamentous Fungi: Proposed Standard. Document M-38P Wayne, PA:
20. Raper K. B., Fennell D. I. 1965 The Genus Aspergillus Baltimore: Williams & Wilkins;
    [Google Scholar]
21. Sanglard D., Odds F. C. 2002; Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2:73–85 [CrossRef]
    [Google Scholar]
22. Symoens F., Bertout S., Piens M. A., Burnod J., Renaud F., Nolard N., Chapuis F., Grillot R. & EBGA (European Group for Research on Biotypes and Genotypes of Aspergillus fumigatus ) Network; (2001; A longitudinal study of lung transplant recipients infected with Aspergillus : genetic polymorphism of A.fumigatus . J Heart Lung Transplant 20:970–978 [CrossRef]
    [Google Scholar]
23. Tortorano A. M., Dannaoui E., Cogliati M., Piens M. A., Rigoni A. L., Grillot R., Viviani M. A. EBGA Network 2000; Evaluation of different in vitro procedures for testing amphotericin B and itraconazole susceptibility of Aspergillus fumigatus . J Mycol Med 10:123–127
    [Google Scholar]
24. Tortorano A. M., Dannaoui E., Meletiadis J. & 7 other authors; 2002; Effect of medium composition on static and cidal activity of amphotericin B, itraconazole, voriconazole, posaconazole and terbinafine against Aspergillus fumigatus : a multicenter study. J Chemother 14:246–252 [CrossRef]
    [Google Scholar]
25. Verweij P. E., Meis J. F., Sarfati J., Hoogkamp-Korstanje J. A., Latge J. P., Melchers W. J. 1996; Genotypic characterization of sequential Aspergillus fumigatus isolates from patients with cystic fibrosis. J Clin Microbiol 34:2595–2597
    [Google Scholar]
26. Verweij P. E., Oakley K. L., Morrissey J., Morrissey G., Denning D. W. 1998a; Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother 42:873–878
    [Google Scholar]
27. Verweij P. E., Voss A., Meis J. F. 1998b; Resistance of Aspergillus fumigatus to itraconazole. Scand J Infect Dis 30:642–643 [CrossRef]
    [Google Scholar]
28. Verweij P. E., Te Dorsthorst D. T., Rijs A. J., De Vries-Hospers H. G., Meis J. F. 2002; Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J Clin Microbiol 40:2648–2650 [CrossRef]
    [Google Scholar]